CVSI CV Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1510964 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.9%
TTM net income YoY-16.2%
TTM EPS YoY—
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—
Margins
Gross margin49.5%
Operating margin-2.5%
Net margin-13.7%
FCF margin-1.5%
EBITDA margin-1.8%
Returns
ROE-90.1%
ROA-25.6%
ROIC (approx.)-12.3%
Asset turnover1.86x
Leverage & solvency
Liabilities / assets64.7%
Debt / equity0.00x
Current ratio1.18x
Interest coverage-1.42x
Cash quality & payout
Operating cash flow / net income0.10x
Accruals ratio-23.0%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $13.79M | $15.71M | $16.00M | $16.20M | $20.05M |
| Cost of revenue | $7.04M | $8.54M | $8.92M | $10.65M | $11.43M |
| Gross profit | $6.75M | $7.17M | $7.08M | $5.55M | $8.62M |
| R&D expense | $122,000 | $118,000 | $151,000 | $307,000 | $1.19M |
| SG&A expense | $7.62M | $9.24M | $9.74M | $12.09M | $25.88M |
| Operating income | -$470,000 | -$2.19M | $3.36M | -$6.85M | -$18.45M |
| Interest expense | $517,000 | $212,000 | — | $600,000 | $38,000 |
| Pretax income | -$949,000 | -$2.40M | $3.10M | -$8.26M | -$15.64M |
| Income tax | $9,000 | -$8,000 | -$6,000 | -$47,000 | -$87,000 |
| Net income | -$958,000 | -$2.39M | $3.10M | -$8.21M | -$15.55M |
| EBITDA | -$278,000 | -$1.86M | $3.60M | -$5.86M | -$17.29M |
| EPS (basic) | -0.01 | -0.01 | 0.02 | -0.07 | -0.14 |
| EPS (diluted) | -0.01 | -0.01 | 0.02 | -0.07 | -0.14 |
| Weighted avg. shares (diluted) | 184.26M | 175.59M | 153.96M | 138.03M | 107.82M |
| Banking | |||||
| Net interest income | — | — | — | -$1.54M | -$140,000 |
| Balance sheet | |||||
| Cash & equivalents | $278,000 | $454,000 | $1.32M | $611,000 | $1.38M |
| Receivables | $402,000 | $522,000 | $431,000 | $766,000 | $2.04M |
| Inventory | $4.09M | $4.90M | $5.66M | $6.56M | $8.62M |
| Current assets | $5.13M | $6.24M | $7.94M | $11.13M | $14.19M |
| PP&E, net | $344,000 | $399,000 | $379,000 | $575,000 | $1.72M |
| Goodwill | $1.01M | $971,000 | $342,000 | $0 | $0 |
| Intangibles | $76,000 | $93,000 | $78,000 | $251,000 | $1.49M |
| Total assets | $6.96M | $7.93M | $9.20M | $12.74M | $18.07M |
| Current liabilities | $5.00M | $6.11M | $6.12M | $13.31M | $14.46M |
| Short-term debt | $1.26M | $677,000 | — | — | $310,000 |
| Long-term debt | $387,000 | $0 | — | — | $0 |
| Total debt | $1.65M | $677,000 | — | — | $310,000 |
| Total liabilities | $5.49M | $6.13M | $6.30M | $13.51M | $14.52M |
| Shareholders' equity | $1.47M | $1.79M | $2.90M | -$777,000 | $3.54M |
| Net debt | $1.37M | $223,000 | — | — | -$1.06M |
| Shares outstanding | 184.26M | 184.26M | 161.68M | 152.10M | 112.48M |
| Cash flow statement | |||||
| Operating cash flow | -$407,000 | -$861,000 | $2.25M | -$1.89M | -$7.49M |
| Capital expenditure | $109,000 | $18,000 | $0 | $0 | $35,000 |
| Free cash flow | -$516,000 | -$879,000 | $2.25M | -$1.89M | -$7.52M |
| Investing cash flow | -$109,000 | -$28,000 | -$156,000 | $0 | -$35,000 |
| Financing cash flow | $337,000 | $32,000 | -$1.39M | $1.12M | $4.37M |
| Depreciation & amortization | $192,000 | $334,000 | $235,000 | $992,000 | $1.15M |
| Stock-based compensation | $497,000 | $258,000 | $218,000 | $1.01M | $3.21M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.